A Synergetic Screening Approach with Companion Effector for Combination Therapy: Application to Retinoblastoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Mahida, Jeni P ^a   Antczak, Christophe ^a   DeCarlo, Daniel ^a   Champ, Kathryn G ^a   Francis, Jasmine H ^a   Marr, Brian ^a   Polans, Arthur S ^b   Albert, Daniel M ^b   Abramson, David H ^a   Djaballah, Hakim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; AVERMECTIN; BERBERINE; BUDESONIDE; CAFFEIC ACID PHENETHYL ESTER; CHELIDONINE; FLOXURIDINE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NOCODAZOLE; PERPHENAZINE; PHORBOL 13 ACETATE 12 MYRISTATE; PIPERAZINE; QUINIDINE; RESVERATROL; THIOGUANOSINE; TOLPERISONE; TOMELUKAST; TRIAMTERENE;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG APPROVAL; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; RETINOBLASTOMA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; REPRODUCIBILITY OF RESULTS; RETINAL NEOPLASMS; RETINOBLASTOMA; SMALL MOLECULE LIBRARIES; STILBENES;

EID: 84875098850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059156     Document Type: Article

References (36)

1. DeVita VT Jr, Rosenberg SA, (2012) Two hundred years of cancer research. N Engl J Med 366: 2207-2214.
2. Bock C, Lengauer T, (2012) Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 12: 494-501.
3. Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, et al. (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 9: 843-856.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
5. Knight ZA, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
7. Holbeck S, Collins J, Doroshow J, (2012) 27 NCI-60 Combination Screening Matrix of Approved Anticancer Drugs. European Journal of Cancer 48: 11.
8. Chen MH, Kerkela R, Force T, (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118: 84-95.
9. Rossi D, Guerrini A, Bruni R, Brognara E, Borgatti M, et al. (2012) trans-Resveratrol in Nutraceuticals: Issues in Retail Quality and Effectiveness. Molecules 17: 12393-12405.
10. Subramanian L, Youssef S, Bhattacharya S, Kenealey J, Polans AS, et al. (2010) Resveratrol: challenges in translation to the clinic-a critical discussion. Clin Cancer Res 16: 5942-5948.
11. Li JW, Vederas JC, (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
12. Qin C, Tan KL, Zhang CL, Tan CY, Chen YZ, et al. (2012) What Does It Take to Synergistically Combine Sub-Potent Natural Products into Drug-Level Potent Combinations? PLoS One 7: e49969.
13. Chantada GL, Qaddoumi I, Canturk S, Khetan V, Ma Z, et al. (2011) Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer 56: 341-348.
14. Antczak C, Kloepping C, Radu C, Genski T, Muller-Kuhrt L, et al. (2009) Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides. Invest Ophthalmol Vis Sci 50: 3065-3073.
15. Patel M, Paulus YM, Gobin YP, Djaballah H, Marr B, et al. (2011) Intra-arterial and oral digoxin therapy for retinoblastoma. Ophthalmic Genet 32: 147-150.
16. Sareen D, van Ginkel PR, Takach JC, Mohiuddin A, Darjatmoko SR, et al. (2006) Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest Ophthalmol Vis Sci 47: 3708-3716.
17. van Ginkel PR, Darjatmoko SR, Sareen D, Subramanian L, Bhattacharya S, et al. (2008) Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. Invest Ophthalmol Vis Sci 49: 1299-1306.
18. Fulda S, (2010) Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 15: 757-765.
19. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6: e19881.
20. Scott E, Steward WP, Gescher AJ, Brown K, (2012) Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol Nutr Food Res 56: 7-13.
21. Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, et al. (2011) The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother 60: 731-738.
22. Fournier GA, Sang DN, Albert DM, Craft JL, (1987) Electron microscopy and HLA expression of a new cell line of retinoblastoma. Invest Ophthalmol Vis Sci 28: 690-699.
23. Hu J, Cheung NK, (2009) Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. Int J Cancer 124: 1700-1706.
24. Ambrosini G, Schwartz G (2010) The MEK inhibitor AZD6244 is active in GNAQ mutant ocular melanoma cells. 17-21.
25. Ma LD, Marquardt D, Takemoto L, (1991) Center MS (1991) Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 266: 5593-5599.
26. Antczak C, Mahida JP, Bhinder B, Calder PA, Djaballah H, (2012) A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. J Biomol Screen 17: 885-899.
27. Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, et al. (2012) Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol.
28. Shum D, Radu C, Kim E, Cajuste M, Shao Y, et al. (2008) A high density assay format for the detection of novel cytotoxic agents in large chemical libraries. J Enzyme Inhib Med Chem 23: 931-945.
29. Antczak C, Shum D, Escobar S, Bassit B, Kim E, et al. (2007) High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen 12: 521-535.
30. Ahmad KA, Clement MV, Hanif IM, Pervaiz S, (2004) Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 64: 1452-1459.
31. Mao QQ, Bai Y, Lin YW, Zheng XY, Qin J, et al. (2010) Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res 54: 1574-1584.
32. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL, (2009) Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486: 95-102.
33. Gadea BB, Ruderman JV, (2005) Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol Biol Cell 16: 1305-1318.
34. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM, (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207-219.
35. Chen ZH, Hurh YJ, Na HK, Kim JH, Chun YJ, et al. (2004) Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 25: 2005-2013.
36. Chun YJ, Kim MY, Guengerich FP, (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262: 20-24.